Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
- Resource Type
- article
- Source
- Neurology and Therapy, Vol 12, Iss 5, Pp 1435-1438 (2023)
- Subject
Anti-AChR antibody Complement Monoclonal antibody Myasthenia gravis Ravulizumab Patient-centered outcomes Neurology. Diseases of the nervous system RC346-429 - Language
- English
- ISSN
- 2193-8253
2193-6536